Search results
Sandoz | 917,578 followers on LinkedIn. Sandoz is the global leader in generic and biosimilar medicines. Our Purpose is to pioneer access to medicines for patients globally.
- Open32.02High32.64Low32.02
- Mkt Cap13.92BP/E (TTM)202.38Div & Yield0.45 & 1.41%
- Prev. Close32.0252 Wk. Low22.7052 Wk. High32.80
Related stocks
Oct 4, 2023 · Oct 04, 2023. Ad hoc announcement pursuant to Art. 53 LR. Novartis executes separation of the Sandoz business to create an independent company by way of a 100% Spin-off. Shares of Sandoz will be listed and commence trading today on the SIX Swiss Exchange.
Learn about Sandoz, a global leader in generic and biosimilar medicines, and a division of Novartis. Discover our mission, vision, and values.
Sandoz Group AG is a Swiss company that focuses on generic pharmaceuticals and biosimilars. Prior to October 2023, it was part of a division of Novartis that was established in 2003, when Novartis united all of its generics businesses under the name Sandoz.
Mar 21, 2023 · Basel, March 21, 2023 – Sandoz, a global leader in generic pharmaceuticals and biosimilars, today announced that the US Food and Drug Administration (FDA) approved a citrate-free high-concentration formulation (HCF) of its biosimilar Hyrimoz ® (adalimumab-adaz) injection.
Explore the products that Sandoz US offers to patients and customers, including generic and biosimilar medicines for various health needs.
Mar 5, 2024 · Basel, March 5, 2024 – Sandoz, the global leader in generic and biosimilar medicines, today announced that the US Food and Drug Administration (FDA) approved Wyost ® (denosumab-bbdz) and ...